Schrodinger

SDGR

Market cap $1.49B

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on October 13, 2025, the company granted restricted stock units (RSUs) with respect to 14,888 shares of the company's common stock to 10 newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on September 14, 2025, the company granted restricted stock units (RSUs) with respect to 1,666 shares of the company's common stock to four newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material induceme.

The average of price targets set by Wall Street analysts indicates a potential upside of 40.4% in Schrodinger (SDGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Schrödinger, Inc. (NASDAQ:SDGR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 11:30 AM EDT Company Participants Ramy Farid - CEO, President & Director Karen Akinsanya - President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships Richie Jain - Executive VP, CFO & Treasurer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to Morgan Stanley's Global Healthcare Conference. I'm Sean Laaman, Head of U.S. Mid-Cap Biotech Equity Research here at the firm.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. The live presentation will take place on Monday, September 8, 2025 at 11:30 a.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery wi.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 15, 2025, the company granted restricted stock units (RSUs) with respect to 1,875 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement t.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Phase 1 dose-escalation study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Despite early evidence of monotherapy activity observed in the Phase 1 study, based on the profile observed to date, including two emergent events where SGR-2921 was consid.

Schrödinger, Inc. (NASDAQ:SDGR ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Jaren Irene Madden - Chief Corporate Affairs Officer & Head of Investor Relations Karen Akinsanya - President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships Ramy Farid - CEO, President & Director Richie Jain - Executive VP, CFO & Treasurer Conference Call Participants Brendan Mychal Smith - TD Cowen, Research Division Evan David Seigerman - BMO Capital Markets Equity Research Lili Nsongo - Leerink Partners LLC, Research Division Michael Leonidovich Ryskin - BofA Securities, Research Division Scott Anthony Schoenhaus - KeyBanc Capital Markets Inc., Research Division Sean M. Laaman - Morgan Stanley, Research Division Operator Thank you for standing by.

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.74 per share a year ago.

Image source: The Motley Fool.